| Company/Division name | Copan Diagnostics |
| Parent company | COPAN Group |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 3.5 |
| Country(ies) from which reshored: | Italy |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | test kits |
| What domestic positive factors made reshoring more attractive? | Proximity to customers/market, Skilled workforce availability/training |
